Richard B Sparks
Overview
Explore the profile of Richard B Sparks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Combs A, Zhu W, Crawley M, Glass B, Polam P, Sparks R, et al.
J Med Chem
. 2006 Jun;
49(13):3774-89.
PMID: 16789735
Potent nonpeptidic benzimidazole sulfonamide inhibitors of protein tyrosine phosphatase 1B (PTP1B) were derived from the optimization of a tripeptide containing the novel (S)-isothiazolidinone ((S)-IZD) phosphotyrosine (pTyr) mimetic. An X-ray cocrystal...
12.
Siegel J, Sparks R, Sharkey R, Wessels B, Bolch W, Bouchet L, et al.
J Nucl Med
. 2005 Aug;
46(8):1404-6.
PMID: 16085600
No abstract available.
13.
Stabin M, Sparks R, Crowe E
J Nucl Med
. 2005 Jun;
46(6):1023-7.
PMID: 15937315
Unlabelled: The OLINDA/EXM version 1.0 personal computer code was created as a replacement for the widely used MIRDOSE3.1 code. This paper documents the basic function of the code and how...
14.
Sparks R, Combs A
Org Lett
. 2004 Jul;
6(14):2473-5.
PMID: 15228307
[reaction: see text] 2,4,5-Triaryl-imidazoles were synthesized directly from the keto-oxime in moderate to good yields via cyclization to the N-hydroxyimidazole and an unprecedented in situ thermal reduction of the N-O...
15.
Wiseman G, Leigh B, Erwin W, Sparks R, Podoloff D, Schilder R, et al.
Cancer Biother Radiopharm
. 2003 Jun;
18(2):165-78.
PMID: 12804042
This was a 30-patient Phase II trial of reduced-dose (90)Y ibritumomab tiuxetan (Zevalin) RIT for patients with low-grade, follicular, or transformed B-cell NHL and mild thrombocytopenia. Patients were given an...
16.
Wiseman G, Kornmehl E, Leigh B, Erwin W, Podoloff D, Spies S, et al.
J Nucl Med
. 2003 Mar;
44(3):465-74.
PMID: 12621016
Unlabelled: Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates (111)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT)....
17.
Siegel J, Stabin M, Sparks R
J Nucl Med
. 2003 Feb;
44(2):320-1; author reply 321-3.
PMID: 12571225
No abstract available.
18.
Siegel J, Yeldell D, Goldenberg D, Stabin M, Sparks R, Sharkey R, et al.
J Nucl Med
. 2003 Jan;
44(1):67-76.
PMID: 12515878
Unlabelled: Calculated red marrow absorbed dose in patients receiving radioimmunotherapy (RAIT) has not been highly predictive of the dose-limiting hematologic toxicity observed in many patient populations studied. Because patients receiving...
19.
Stabin M, Siegel J, Sparks R
Cancer Biother Radiopharm
. 2002 Dec;
17(5):535-43.
PMID: 12470423
We have investigated several of the key model parameters and assumptions involved in the calculation of red marrow absorbed dose in order to better understand the sensitivity of the predicted...
20.
Siegel J, Marcus C, Sparks R
J Nucl Med
. 2002 Sep;
43(9):1241-4.
PMID: 12215565
Unlabelled: In calculations of absorbed doses from radioactive patients, the activity distribution in such patients is generally assumed to be an unattenuated point source and the dose to exposed individuals...